TAPUR Clinical Trial: Matching Mutations to FDA approved Drugs

If you are dealing with metastatic disease and know your genetic mutations, there is a large clinical trial (called "TAPUR") that allows you to obtain FDA-approved targeted drugs that match a genomic abnormality, even when the drugs have not been approved to treat metastatic breast cancer. Very cool.

For more details, read this July 2016 article.
http://www.sharecancersupport.org/share-new/learn/blog/TAPUR

Trial website: https://clinicaltrials.gov/ct2/show/NCT02693535
Estimated Enrollment: 1030
Study Start Date: March 2016
Estimated Primary Completion Date: March 2019

TRIAL LOCATIONS include (at the moment): Idaho, Michigan, North Carolina, South Carolina.
ASCO is working to add sites across the country.

Here's the different drugs. Compare your mutations against the list below to see if there is a match.

ARMS:
Group 1 (VEGFR)
Participants receive axitinib - dosage, frequency and duration per label VEGFR mutation, amplification or overexpression)
Drug: Axitinib. Other Name: Inlyta

Group 2 (Bcr-abl, SRC, LYN, LCK)
Participants receive bosutinib- dosage, frequency and duration per label Bcr-abl, SRC, LYN, LCK mutations
Drug: Bosutinib. Other Name: Bosulif

Group 3 (ALK, ROS1, MET)
Participants receive crizotinib - dosage, frequency and duration per label ALK, ROS1, MET mutations
Drug: Crizotinib. Other Name: Xalkori

Group 4 (CDKN2A/p16, CDK4, CDK6)
Participants receive palbociclib - dosage, frequency and duration per label CDKN2A/p16 loss, CDK4, CDK6 amplifications
Drug: Palbociclib. Other Name: Ibrance

Group 5 (CSF1R, PDGFR, VEGFR)
Participants receive sunitinib - dosage, frequency and duration per label CSF1R, PDGFR, VEGFR mutations
Drug: Sunitinib. Other Name: Sutent

Group 6 (mTOR, TSC)
Participants receive temsirolimus - dosage, frequency and duration per label mTOR, TSC mutations
Drug: Temsirolimus. Other Name: Torisel

Group 7 (EGFR)
Participants receive erlotinib - dosage, frequency and duration per label EGFR mutations
Drug: Erlotinib. Other Name: Tarceva

Group 8 (ERBB2)
Participants receive trastuzumab and pertuzumab - dosage, frequency and duration per label (ERBB2 amplifications)
Drug: Trastuzumab and Pertuzumab. Other Name: Herceptin and Perjeta

Group 9 (BRAFV600E)
Participants receive vemurafenib and cobimetinib - dosage, frequency and duration per label BRAFV600E mutations
Drug: Vemurafenib and Cobimetinib. Other Name: Zelboraf and Cotellic

Group 10 (PTCH1)
Participants receive vismodegib - dosage, frequency and duration per label PTCH1 deletion or inactivating mutations
Drug: Vismodegib. Other Name: Erivedge

Group 11 (KRAS, NRAS and BRAF)
Participants receive cetuximab - dosage, frequency and duration per label KRAS, NRAS and BRAF wildtype
Drug: Cetuximab. Other Name: Erbitux

Group 12 (Bcr-abl, SRC, KIT, PDGFRB, EPHA2, FYN, LCK, YES1)
Participants receive dasatinib- dosage, frequency and duration per label Bcr-abl, SRC, KIT, PDGFRB, EPHA2, FYN, LCK, YES1 mutations
Drug: Dasatinib. Other Name: Sprycel

Group 13 (RET, VEGFR1/2/3, KIT, PDGFRβ, RAF-1, BRAF)
Participants receive regorafenib- dosage, frequency and duration per label RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFRβ, RAF-1, BRAF mutations/amplifications
Drug: Regorafenib. Other Name: Stivarga

Group 14 (BRCA1 / BRCA2; ATM)
Participants receive olaparib- dosage, frequency and duration per label Germline or somatic BRCA1/BRCA2 inactivating mutations; ATM mutations or deletions
Drug: Olaparib. Other Name: Lynparza

Group 15 (POLE / POLD1)
Participants receive pembrolizumab- dosage, frequency and duration per label
Drug: Pembrolizumab. Other Name: Keytruda [This is a Immunotherapy drug]